METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression

Yu-qing Guo1†, Qiang Wang2†, Jun-guo Wang3,4†, Ya-jun Gu3,4, Pan-pan Song3,4, Shou-yu Wang1,2,5*, Xiao-yun Qian1,3,4,6* and Xia Gao1,3,4,6*

Abstract

Background: N6-methyladenosine (m6A) RNA methylation and its methyltransferase METTL3 have been widely reported to be involved in different cancers by regulating RNA metabolism and function. Here, we aimed to explore the biological function and clinical significance of m6A modification and METTL3 in head and neck squamous cell carcinoma (HNSCC).

Methods: The prognostic value of METTL3 expression was evaluated using tissue microarray and immunohistochemical staining analyses in a human HNSCC cohort. The biological role and mechanism of METTL3 in HNSCC tumour growth, metastasis and angiogenesis were determined in vitro and in vivo.

Results: M6A levels and METTL3 expressions in HNSCC tissues were significantly increased compared with paired adjacent tissues. Meanwhile, METTL3 was an independent risk factor for the prognosis of HNSCC patients. Moreover, METTL3 overexpression promoted HNSCC cell proliferation, migration, invasion, and angiogenesis, while knockdown of METTL3 had an opposite effect in vivo and in vitro. Mechanistically, METTL3 enhanced the m6A modification of CDC25B mRNA, which maintained its stability and upregulated its expression, thereby activating G2/M phase of cell cycle and leading to HNSCC malignant progression.

Conclusions: METTL3 may be a potential prognostic biomarker and therapeutic target for HNSCC.

Keywords: m6A, METTL3, CDC25B, Cell cycle, HNSCC

Introduction

Head and neck tumor is the sixth most common cancer in the world, including the malignant tumors in the oral cavity, oropharynx, hypopharynx, and pharynx. Of all, head and neck squamous cell carcinoma (HNSCC) accounts for more than 90% of the most common histological type of head and neck tumor [1, 2]. New cases of HNSCC exceed 1,000,000 each year, with 543,000 death around the world [3]. Smoking and drinking have been proved to be the most important risk factors for HNSCC [4, 5]. Meanwhile, it also showed that human papillomavirus (HPV) is a strong independent risk factor for HNSCC [6]. Currently, surgery, radiotherapy, and/or chemotherapy are the conventional treatment for HNSCC. Although there are some improvements for HNSCC therapy, the outcome of patients with HNSCC remains poor, especially for patients with advanced...
called writer and eraser, respectively); m6A modification is mainly controlled by methyltransferase and demethylase (also known as reader) could bind to the m6A motif and regulate RNA function [14, 16], including RNA splicing, polyadenylation, mRNA stability, mRNA localization, and translation [9]. N6-methyladenosine (m6A) is one of the most abundant RNA modifications in eukaryote RNA, which accounts for about 50% of total modifications [10, 11]. It has been reported that m6A modification usually enriches around stop codon and 3’-UTR region, and participates in each period of the RNA metabolism [12–14]. M6A modification is mainly controlled by methyltransferase and demethylase (also called writer and eraser, respectively); m6A methyltransferases have shown promising clinical value for cancer therapy [15]; and m6A binding protein (also called reader) could bind to the m6A motif to regulate RNA function [14, 16], including RNA splicing, stability, transport, localization, and translation, which has been reported to play a critical role in multiple biological processes like tumorigenesis and hematopoiesis [17, 18].

METTL3 is the first identified and acts as the major catalytic component of the m6A methyltransferase complex. The biological functions of METTL3 have been widely studied to be involved in different aspects of cancer development. With the development of high-throughput sequencing and detection technology, lots of m6A modification-related RNAs have been found to be the potential cancer biomarkers and therapeutic targets [19, 20]. Lots of studies have showed that abnormal expression of METTL3 in acute myeloid leukemia (AML) [21, 22], gastric cancer [23, 24], pancreatic cancer [25], breast cancer [26], hepatocellular carcinoma [27], and non-small cell lung cancer (NSCLC) [28] is associated with various diseases, including cancer progression and resistance to therapy [31]. It has also been reported that METTL3 could increase YAP mRNA stability and translation, and promote NSCLC metastasis and therapy resistance [31]. However, the role of METTL3 in HNSCC field is unclear, which pushes us to explore its function in HNSCC development.

CDC25 is a highly conserved phosphatase with dual serine and threonine specificity, which consists of 3 subtypes, CDC25A, CDC25B, and CDC25C. The N terminal region of CDC25 has phosphorylation and ubiquitination site to regulate phosphatase activity, while the C terminal region contains the catalytic site [32]. CDC25B dephosphorylates and activates cyclin-dependent kinase/cyclin complex (CDK1/Cyclin B), which is responsible for cell cycle G2-M transition [33–36]. It has reported that CDC25B inhibitors (vitamin K analogs like adcaquinone B [37], NSC 663284 [38], and menadione [39]) could inhibit CDC25B diphosphatase activity and suppress tumor progression. However, the function of CDC25B in HNSCC remains elusive.

In this study, we revealed that METTL3 could mediate m6A modification on CDC25B mRNA and promote the malignant progression of HNSCC, proposing that METTL3 may be a potential predictive biomarker and therapeutic target for HNSCC.

Materials and methods

Patients and specimens

All HNSCC and paracancerous normal frozen tissues were collected from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (Nanjing, Jiangsu, China), including 5 pairs of HNSCC with paracancerous normal tissues and 100 HNSCC tissues used for tissue microarray. The selection criteria were as follows: patients diagnosed with primary HNSCC who have
Fig. 1 (See legend on previous page.)
not received any treatment other than surgical resection from 2013 to 2017. They were used for qRT-PCR, western blotting, dot blotting, and IHC assay. The Nanjing Drum Tower Hospital Ethics Committee has endorsed this study.

**Cell culture and transfection**

Human HNSCC cell lines (SAS, FaDu, Hep2, Tu212, and Tu686) were purchased from Yaji Biotechnology (Shanghai, China). Human HUVEC cell was obtained from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). HUVEC, SAS, FaDu, Tu212, and Tu686 cell lines were cultured in RPMI-1640 medium. Hep2 cell was cultured in DMEM medium. siRNA, plasmid transfection, and viral transduction were performed as previously reported[23].

**shRNA, plasmid, and siRNA construct**

All shRNA and plasmid were constructed as our previous study[23]. METTL3 shRNA, METTL3 cDNA were cloned into lentiviral vectors. CDC25B siRNAs were obtained from RiboBio (Guangzhou, China). All sequences can be seen in the Additional file 1: Table S2.

**Tissue microarray (TMA) and Immunohistochemistry staining**

The HNSCC TMA were made in the Department of Pathology in Nanjing Drum Tower Hospital. IHC on tissue sections was carried out as previously described [23]. Scoring was conducted independently by two pathologists with the semi-quantitative immunoreactivity score (IRS) standard as previously reported [23]. The final score was designated as low or high expression group using IRS: low expression was defined as an IRS of 0–6, and high expression as an IRS of 8–12.

**Human m6A-mRNA epitranscriptomic microarray**

Total RNA was extracted from METTL3 knockdown SAS cells and the corresponding control cells, and was incubated with an anti-m6A antibody and magnetic beads for immunoprecipitation. After eluting, we tagged m6A modified RNA as “IP” and labeled with Cy5, and unmodified RNA in the supernatant as “Sup” and labeled as Cy3, they were then used as cRNAs in analysis using Arraystar Super RNA Labeling Kit. After hybridizing these cRNAs onto a Arraystar Epitranscriptomic Microarray slide (8 × 60 K, Arraystar) and washing it, an Agilent Scanner G2505C was used to scan the array. A normalization was done on the raw intensities of Cy5-labeled “IP” and Cy3-labeled “Sup” using an average of log2-scaled Spike-in RNA intensities. These intensities gave the basis to calculate m6A methylation level and quantity. Differentially m6A-methylated RNAs were filtered by fold change > 1.2 and p-value < 0.05, and then be used for hierarchical clustering, GO analysis and pathway analysis.

**Dot blot assay**

The dot blot assay was conducted as previously described [23]. mRNA was extracted and denatured. After adding mRNA to a Hybond-N + membrane, the membrane was crosslinked, washed, blocked in blocking buffer, and incubated with an anti-m6A antibody. The membrane was then washed and incubated with an anti-mouse antibody. After washing, Hyperfilm ECL was added onto the membrane and then images were acquired. The loading control was constructed with methylene blue interacting with mRNA.

**The mRNA stability assay**

The actinomycin D (MCE, San Dimas, CA, USA) was used to inhibit RNA synthesis. The concentration used was 5 µg/mL. Cells were collected at different time points (0, 4 or 8 h) after actinomycin D treatment. Total RNA was then extracted and analyzed by qRT-PCR. The remaining RNA levels at each time point were normalized to the level at the beginning (0 h).

(See figure on next page.)

**Fig. 2** METTL3 promotes HNSCC cell proliferation, migration, and invasion. A The protein levels of METTL3 in SAS cells with METTL3 knockdown were measured by western blotting (upper panel), and cell proliferation ability in METTL3 knockdown and their corresponding control SAS cells were measured by a CCK8 assay (bottom panel). B The protein levels of METTL3 in FaDu cells with METTL3 knockdown were measured by western blotting (upper panel), and cell proliferation ability in METTL3 knockdown or control FaDu cells were measured by a CCK8 assay (bottom panel). C The protein levels of METTL3 in Hep2 cells with METTL3 overexpression were measured by western blotting (upper panel), and cell proliferation ability in METTL3 knockdown or control Hep2 cells were measured by a CCK8 assay (bottom panel). D, E, F knockdown of METTL3 inhibits HNSCC cell proliferation by colony formation assay (left panel). Quantification of the colony formation assay results (right panel). F METTL3 overexpression promotes HNSCC cell proliferation by colony formation assay (left panel). G, H Knockdown of METTL3 inhibits HNSCC cell migration and invasion by transwell assays. Representative images (scale bars = 100 μm, left panel) and quantification (right panel) of the cell migration and invasion assay results were shown. I METTL3 overexpression promotes HNSCC cell migration and invasion by transwell assays. Representative images (scale bars = 100 μm, left panel) and quantification (right panel) of the cell migration and invasion assay results were shown. The data are the means ± SD of three independent experiments. */# p < 0.05, **/*# p < 0.01, ***/# p < 0.001, ****/# p < 0.0001.
Fig. 2 (See legend on previous page.)
Western blot assay and Quantitative real-time RT-PCR (qRT-PCR)
Western blot assay and qRT-PCR were performed as previously described[23]. The primers and antibodies were listed in Additional file 1: Tables S2 and S3.

Proliferation and cell cycle assay
For the colony formation assay, HNSCC cells were seeded in 12-well plates (500 cells per well) and incubated in a carbon dioxide cell incubator for 8–12 days. Cells were then fixed with methanol and stained with crystal violet (Beyotime) for 30 min each.

For the CCK8 assay, 1000 cells were plated in 96-well plates for 24, 48, 72, 96, and 120 h before determining cell viability using the manufacturer’s protocol (Dojindo, Kumamoto, Japan). When adding menadione, different concentrations were added in wells after cell adhesion (about 6 h).

The cell cycle assay was performed according to the Cell Cycle Staining Kit protocol (MultiScience, Hangzhou, China). After collecting 2 × 10^5–1 × 10^6 cells, 1 ml DNA staining solution and 10 μl permeabilization solution were added and then vortexed for 5-10 s. Cell cycle phases were detected on a flow cytometer after 30 min incubation in dark at room temperature.

Transwell assay
Transwell assay was performed as previously described [23]. Briefly, after coating the upper transwell chambers with or without Matrigel (BD, Bioscience), HNSCC cells were seeded with serum-free medium, and medium containing 10%FBS was added in the lower chambers. Chambers were incubated, fixed with paraformaldehyde, stained crystal violet, and then imaged.

Animal study
BALB/c male nude mice (5–6 weeks old) were purchased from Nanjing Biomedical Research Institute of Nanjing University (Nanjing, Jiangsu, China) and maintained in SPF facilities. Tumour xenograft models were established in nude mice bearing: SAS cells cells stably transfected with METTL3-shRNA and the corresponding control vector. The different HNSCC cells (5 × 10^6) were subcutaneously injected into the right axilla of nude mice (n = 6 per group). Tumour volume was monitored every other day (volume = length × width^2 × 1/2). At the end of the experiment, the mice were sacrificed, and the tumors were weighed and imaged and were then fixed in 4% paraformaldehyde or frozen for further analyses.

HUVEC tube formation assay
HUVEC tube formation assay was conducted as previously reported [23]. HNSCC cells were cultured and the conditioned medium was mixed with HUVEC cells in 96-well plates coated with Matrigel™(BD Biosciences). After incubating for 24 h, images were taken and 3 random fields were used to count tubes.

Statistical analysis
Pearson Chi-Square test was used to evaluate IHC scores of HNSCC and paracancerous normal tissues, as well as METTL3 expression with clinicopathological features. Wilcoxon test (grouped) was used to assess IRS differences for the METTL3 high and low expression group. Kaplan–Meier curve with a low-rank test was used to analyze survival differences. The two-tailed Student’s t-test and one-way ANOVA test were used to compare difference significance between 2 and 3 groups.

(See figure on next page.)

**Fig. 3** METTL3 mediates the m6A modification on CDC25B mRNA in HNSCC. A m6A-mRNA epitranscriptomic microarray showed signal pathways in which most differentially expressed gene enriched in METTL3 knockdown cells (SAS), DE represents differentially expressed. B m6A-mRNA epitranscriptomic microarray showed signal pathways in which most differentially methylated genes enriched in METTL3 knockdown cells (SAS), DM represents differentially methylated. C m6A-mRNA epitranscriptomic microarray showed an overlap of the total differentially expressed gene, total differentially methylated gene, and differentially expressed and methylated gene enriched in the cell cycle pathway. D Genes selected from the overlap were used for qRT-PCR in METTL3 knockdown and their corresponding control cells, and CDC25B was the most significantly downregulated gene upon knockdown of METTL3. E, F CDC25B mRNA expression was confirmed by qRT-PCR in METTL3 knockdown (FaDu) and METTL3 overexpression (HeP2) cells. G CDC25B protein level was measured by western blot assay in METTL3 knockdown FaDu cells. H CDC25B protein level was measured by western blot assay in METTL3 overexpressed Hep2 cells. J MeRIP-qPCR was conducted to detect the m6A level of CDC25B mRNA in METTL3 knockdown (SAS) cells. K MeRIP-qPCR was conducted to detect the m6A level of CDC25B mRNA in METTL3 knockdown (FaDu) cells. L, M The levels of CDC25B expression in METTL3 knockdown and their corresponding control cells treated with actinomycin D (5 μg/ml) at the indicated time points were detected by qRT-PCR. The data are the means ± SD of three independent experiments. */# p<0.05; */## p<0.01; **/### p<0.001; */***/#### p<0.0001
Fig. 3 (See legend on previous page.)
Results

High expression of METTL3 in HNSCC correlates with poor prognosis

To investigate the role of m6A modification in HNSCC, we first examined the RNA m6A levels in 7 HNSCC tissues and paracancerous normal tissues via dot blot assay, and the results showed that RNA m6A levels were significantly higher in HNSCC tissues (Fig. 1A). Since m6A modification is regulated by its writers and erasers, and then we analyzed the expression of the main writers and erasers using the Cancer Genome Atlas (TCGA) data, and found the main m6A writers (METTL3, METTL14, WTAP, RBM15) and erasers (FTO, ALKBH5) were significantly increased in HNSCC tissues than normal tissues (Fig. 1B, Additional file: Figure S1A). However, high expression of METTL3 correlates with worse disease-free survival (DFS), while there was no correlation between the expression of other writers/erasers and prognosis of HNSCC patients (Fig. 1C, Additional file: Figure S1B). Further, we confirmed that METTL3 mRNA and protein expression were significantly higher in HNSCC tissues compared with paired normal tissues, respectively (Fig. 1D, E). In addition, these results were also confirmed by immunohistochemistry (IHC) staining, showing the expression of METTL3 was significantly increased in HNSCC tissues compared with that in matched normal tissues (Fig. 1F). Besides, high METTL3 expression in cancerous tissues was significantly correlated with advanced T stage and poor tumor differentiation among HNSCC patients (Additional file: Table S1), and HNSCC patients with high expression of METTL3 had worse overall survival using our tissue microarray (TMA) (n = 100, p = 0.001; Fig. 1G, Additional file: Figure S2A). Simultaneously, univariate Cox regression analysis revealed that tumor grade, clinical stage, TNM stage, and METTL3 expression were substantially associated with the overall survival of HNSCC patients (Fig. 1H), and multivariate Cox regression analysis showed that only METTL3 expression was an independent prognostic factor for HNSCC patients (Fig. 1I). Meanwhile, we further analyzed the time-dependent receiver operating characteristic (ROC) curve to assess the predictive ability of METTL3 expression for HNSCC prognosis. When combined METTL3 risk score and clinical risk score, the area under the curve (AUC) is the highest, meaning that the combination of clinical risk score (TNM stage) and METTL3 risk score contributed much more than either one alone in these HNSCC patients (Fig. 1J). Taken together, these results revealed that m6A modification and METTL3 expression were higher in HNSCC and METTL3 may be an independent prognostic marker for HNSCC patients.

METTL3 promotes HNSCC cell proliferation, migration, and invasion

To investigate the function of METTL3 in HNSCC, we first detected its expression in five different HNSCC cell lines via qPCR and western blot (Additional file: Figure S2B, C). The results showed that METTL3 was expressed relatively higher in SAS, FaDu, and Tu686, while lower in Hep2 and Tu212 cell lines. We then established the stable METTL3 knockdown cells (SAS and FaDu), and METTL3-overexpressing cells (Hep2) via METTL3 shRNA or overexpression lentivirus plasmid, respectively (Fig. 2A–C, Additional file: Figure S2D). Further, we conducted a series of functional studies, and the result of CCK8 assay showed that down-regulation of METTL3 significantly decreased cell proliferation, while up-regulation of METTL3 showed an opposite effect (Fig. 2A–C). The colony formation assay was also confirmed that down-regulation of METTL3 significantly decreased, while up-regulation of METTL3 increased the number of colonies (Fig. 2D–F). To determine the roles of METTL3 in HNSCC metastasis, we also performed migration and invasion assays, and the results revealed
Fig. 4 (See legend on previous page.)
that knockdown of METTL3 suppressed the migration and invasion of SAS and FaDu cells, however, overexpression of METTL3 dramatically promoted these effects in Hep2 cells (Fig. 2G–I).

METTL3 mediates the m6A modification of CDC25B in HNSCC

To explore the molecular mechanism by which METTL3 promotes HNSCC progression, we performed the m6A-mRNA epitranscriptomic microarray in METTL3 knockdown and the corresponding control HNSCC cells. The results showed that 7476 transcripts were significantly down-regulated (fold change >2) and m6A peaks of 4797 transcripts exhibited significantly decreased abundance (fold change >2) on METTL3 knockdown (Additional file 4: Figure S3A, B). Differentially expressed genes in mRNA expression and m6A-modified peaks were enriched in many signal pathways, and the cell cycle pathway is overlapped (Fig. 3A, B). Furthermore, we found 12 cell cycle-related genes were overlapped (Fig. 3C). Then, the mRNA levels of 8 genes (fold change >2) from the 12 candidates were verified in the METTL3 knockdown SAS cells. It showed that the expression of CDC25B was the most significantly down-regulated (Fig. 3D), which was also confirmed in FaDu cells with METTL3 deficiency (Fig. 3E). Consistently, CDC25B was upregulated in Hep2 cells with METTL3 overexpression (Fig. 3F). Meanwhile, TCGA data also showed a positive correlation between METTL3 and CDC25B (Additional file 4: Figure S3C). Further, CDC25B protein levels were also positively regulated by METTL3 in different HNSCC cell lines (Fig. 3G–I). In addition, the enrichment of m6A modification on CDC25B mRNA was significantly decreased in METTL3 knockdown cells compared with the corresponding control cells using MeRIP-qPCR assay (Fig. 3J, K). Furthermore, when cells were treated with transcription inhibitor actinomycin D, CDC25B mRNA was shown to be less stable on METTL3 knockdown (Fig. 3L, M). These data suggest that METTL3-mediated CDC25B m6A modification and enhanced its mRNA stability regulates its expression in HNSCC.

CDC25B promotes HNSCC cell proliferation, migration, invasion and cell cycle progression

To further investigate the role of CDC25B in HNSCC, we first designed 2 different specific siRNAs targeting CDC25B and confirmed their knockdown efficiency via qPCR and western blot assay (Fig. 4A, B, Additional file 5: Figure S4A, B). Knockdown of CDC25B significantly suppressed the colony formation, cell migration and invasion (Fig. 4C, D, Additional file 5: Figure S4C, D). Furthermore, it showed that menadione, a special inhibitor of CDC25B, could significantly inhibit HNSCC cell growth with an increase of treatment times and doses (Fig. 4E, Additional file 5: Figure S4E). It also indicated that there was no obvious cytotoxicity with the treatment of 5 μM menadione for 24 h (Fig. 4E, Additional file 5: Figure S4E). However, the ability of colony formation, cell migration and invasion were dramatically decreased in the cells treated with 5 μM menadione for 24 h (Fig. 4F, G, Additional file 5: Figure S4F, G). Considering CDC25B is a cell cycle kinase, cell cycle in HNSCC cells was detected using flow cytometry assay. We found G2/M arrest upon CDC25B knockdown or treated with menadione, as well as METTL3 knockdown (Fig. 4H, I, Additional file 5: Figure S4H, I, Additional file 6: Figure S5A, B). Thus, our data suggested that CDC25B could regulate HNSCC progression.

METTL3 promotes HNSCC progression via modulating CDC25B m6A modification

We further confirm the functional role of METTL3-mediated m6A modification of CDC25B in HNSCC. As expected, the expression of CDC25B was knocked down in METTL3-overexpressing Hep2 cells using its specific siRNAs, which markedly suppressed METTL3-induced HNSCC cell proliferation (Fig. 5A). Similarly, it also showed the similar phenotype using 5 μM menadione...
Fig. 5  (See legend on previous page.)
to inhibit CDC25B activity (Fig. 5B). Meanwhile, the HNSCC cell migration and invasion ability were significantly increased upon METTL3 overexpression but were reversely inhibited upon knockdown of CDC25B expression or inhibition of its activity with menadione (Fig. 5C, D). In addition, upregulation of METTL3 promoted cell cycle progression and G2/M proportion was decreased, but knockdown of CDC25B expression or inhibition of its activity with menadione, the G2/M transition was arrested (Fig. 5E, F). Thus, the data suggest that METTL3 promotes HNSCC malignant progression through the upregulation of CDC25B.

**METTL3 accelerates tumor growth and angiogenesis in vivo**

To investigate the function of METTL3 in vivo, we also performed tumor xenograft in nude mice. It showed that knockdown of METTL3 significantly restrained tumor growth (Fig. 6A), as reflected by tumor volume and weight (Fig. 6B, C). As confirmed by qPCR and western blot, CDC25B expression was downregulated upon knockdown of METTL3 in tumor tissues (Fig. 6D, E). Consistently, IHC results also showed that CDC25B staining was also obviously decreased in tumor xenograft with deficiency of METTL3 (Fig. 6F). In addition, IHC staining with Ki67 confirmed that knockdown of METTL3 significantly restrained proliferation markers (Ki67 and PCNA) in HNSCC TCGA data (Additional file 6: figure S5C, D). Furthermore, we found that tumors derived from vector control cells exhibited more blood vessels (Fig. 6A) and it also showed a positively correlation between METTL3 and VEGFA expression (Additional file 6: figure S5E). IHC staining with CD31, a marker of angiogenesis, also showed a significant decreased in tumor tissues of the METTL3 knockdown group compared with that in the control group (Fig. 6G). To further study the function of METTL3 in HNSCC angiogenesis, human umbilical vein endothelial cell (HUVEC) tube formation was investigated in vitro. The HUVEC tube formation was significantly impaired by conditioned medium from SAS cells with knockdown of METTL3 compared with conditioned medium from the vector controls (Fig. 6H); Correspondingly, tube formation was significantly increased by conditioned medium from Hep2 cells with METTL3 overexpression (Fig. 6I). Collectively, these results suggest that METTL3/CDC25B promotes HNSCC tumor growth and angiogenesis.

**Discussion**

In the present study, we demonstrated that m6A modification and METTL3 levels are increased in HNSCC, and METTL3 might be an independent prognostic factor for HNSCC patients. Mechanistically, METTL3 acts as an oncogene to promote cell proliferation, migration, invasion, and angiogenesis in HNSCC through the m6A-mediated upregulation of CDC25B (Fig. 6J).

Epigenetic modifications, especially the abnormal genome methylations have been widely reported in the malignant progression of HNSCC. For example, the tumor suppressor NDRG1 and NDRG2 present highly methylated and low protein expression status in laryngeal cancer, suggesting that abnormal methylation on the NDRG1/2 promoter region may be an early event in laryngeal cancer initiation [40]. In oral squamous cell carcinoma that happened in an Asian population, hypomethylation of Alu, a short interspersed element, decreased as the tumor progresses [41]. Some studies also showed that widely hypomethylation occur in tongue squamous cell carcinoma [42]. It also reported that hypermethylation of the promoter region of the tumor suppressor PTEN could be seen in oral squamous cell carcinoma and nasopharyngeal carcinoma [43–45].
Fig. 6 (See legend on previous page.)
RNA epigenetic modification is the chemical basis for RNA regulation, and more than 170 modifications have been identified [46, 47]. With some related enzymes, RNA could have many epigenetic modifications like N6-Methyladenosine (m6A), pseudouridine (Ψ), 5-methylcytosine 57 (m5C), 5-hydroxymethylcytosine (5hmC), 7-methylguanosine (m7G), and N1-methyladenosine (m1A), which can affect the RNA stability, translation efficiency and others [12, 48, 49]. M6A is the most prevalent in mRNA and non-coding RNA, and recent studies have revealed that m6A and its related regulators play a critical role in various cancers, including cervical cancer [50], breast cancer [51], pancreatic cancer [52], esophageal cancer [53], and prostate cancer [54]. The m6A modification is mainly regulated by m6A methyltransferases (writers), demethylases (erasers), and specific RNA-binding proteins (readers) [14]. Lots of studies showed that altered expression of m6A regulators could increase the occurrence and development of digestive system tumour, and modulation of m6A modification could be the potential therapy for tumour. For example, tumour cells may become more sensitive to chemotherapy, radiotherapy and immunotherapy upon overexpression or knockout of the m6A-related regulators [55]. Here, we indicate that in HNSCC, upregulation of the m6A methyltransferase METTL3 increases m6A level and is associated with worse clinical prognosis for HNSCC patients. In addition, high expression of METTL3 was associated with high T stage and low differentiation. Further, in vitro and in vivo studies indicated that METTL3 promotes HNSCC tumor growth, as well as cell proliferation, migration, invasion, cell cycle progression, and angiogenesis. Consequently, our data suggested that METTL3 may act as an independent prognostic factor and therapeutic target for HNSCC patients.

From m6A-mRNA epitranscriptomic microarray, we found that CDC25B was the pivotal downstream molecular of METTL3 in HNSCC. CDC25B is a cell cycle related enzyme that is critical for G2/M transition. Studies have showed that highly expression of CDC25B in many types of cancer like esophageal squamous carcinoma [56], colorectal cancer [57], non-small cell lung cancer [58], endometrial carcinoma [59], pancreatic ductal adenocarcinoma [60], and breast cancer [61]. However, the function of CDC25B have not been reported in HNSCC. CDC25B can dephosphorylate and activate AMP-activated protein kinase signaling (AMPK) by inhibiting protein phosphatase 2A (PPA2) [62]. Our data showed that in HNSCC, CDC25B was positively regulated by METTL3 by catalyzing the m6A modification on its mRNA, leading to increased cell proliferation, migration, invasion, and cell cycle progression.

**Conclusion**

Our findings indicate that METTL3 acts as an oncogene in HNSCC by regulating m6A modification of CDC25B, a cell cycle protein. Moreover, METTL3 is expressed significantly higher in HNSCC and is associated with a poor prognosis. Consequently, METTL3 may provide a promising future in HNSCC diagnosis and treatment.

**Abbreviations**

3'UTR: 3’Untranslated region; ShmC: 5-Hydroxymethylcytosine; ALKBH5: Alpha-keto glutarate-dependent dioxygenase AlkB homolog 5; Alu: Alumina; AML: Acute myeloid leukemia; AMP: Adenylyl imidodiphosphate; ANOVA: Analysis of variance; CCK8: Cell Counting Kit-8; CD31: Cluster of differentiation 31; CDC25B: Cell division cycle 25 B; CDK1: Cyclin-dependent kinases 1; DFS: Disease-free survival; DMEM: Dulbecco’s Modified Eagle Medium; DMSO: Dimethyl sulfoxide; FBS: Fetal bovine serum; FTO: Alpha-keto glutarate-dependent dioxygenase; GO analysis: Gene ontology analysis; HNSCC: Head and neck squamous cell carcinoma; HPV: Human papillomavirus; HUVEC: Human umbilical vein endothelial cell; IgG: Immunoglobulin G; IHC: Immunohistochemical; MRK67: Marker of proliferation Ki-67; m1A: N1-methyladenosine; m5C: 5-Methylcytosine; m6A: N6-methyladenosine; m7G: 7-Methylguanosine; MeRIP-qPCR: Methyl-RNA immunoprecipitation and quantitative polymerase chain reaction; METTL14: Methyltransferase Like 14; METTL3: Methyltransferase Like 3; mRNA: Messenger RNA; NDRG1/2: N-Myc Downstream Regulated 1/2; NSCLC: Non-small cell lung cancer; PBS: Phosphate buffered saline; PCNA: Proliferating cell nuclear antigen; PTEN: Phosphatase and tensin homolog; QRT-PCR: Quantitative real-time polymerase chain reaction; RBM15: RNA binding motif protein 15; ROC curve: Receiver operating characteristic curve; RPMI-1640: Roswell Park Memorial Institute 1640; shRNA: Short hairpin RNA; siRNA: Small interfering RNA; TCGA: The Cancer Genome Atlas; TMA: Tissue microarray; TNM stage: Tumour, node and metastasis stage; VEGFA: Vascular Endothelial Growth Factor A; WTAP: WT1 associated protein.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s40164-022-00256-3.
Contact the author if need the datasets generated during and/or analysed. Availability of data and materials

Additional file 5: Figure S4. CDC25B promotes cell proliferation, migration, invasion, and cell cycle progression in FaDu cells. (A) The qRT-PCR was conducted to confirm CDC25B knockdown efficiency at mRNA level. (B) Western blot assay was conducted to confirm CDC25B knockdown efficiency at protein level. (C) Knockdown of CDC25B inhibited cell proliferation in colony formation assay (left panel); quantification results of colony formation (right panel). (D) CDC25B knockdown inhibited cell migration and invasion by transwell assays. Representative images (scale bars=100μm, left panel) and quantification (right panel) of the cell migration and invasion assay results were shown. (E) CDC25B knockdown cells (H) and METTL3 knockdown cells (I). The data are the means±SD of three independent experiments. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Additional file 6: Figure S5. CDC25B inhibition results in G2/M arrest, and METTL3 expression has a positive correlation with MKI67, PCNA, and VEGFA. (A) Cell cycle assay of METTL3 knockdown SAS cells treated with 5μM (left panel), percentage of cell cycle phase were calculated (right panel). (B) Cell cycle assay of METTL3 knockdown FaDu cells treated with 5μM menadione for 24h and for used for transwell assays, showing that menadione can inhibit cell migration and invasion. Representative images (scale bars=100μm, left panel) and quantification (right panel) of the cell migration and invasion assay results were shown. Cell cycle G2/M arrest was observed in CDC25B knockdown cells (H) and METTL3 knockdown cells (I). The data are the means±SD of three independent experiments. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001.

Acknowledgements
Not applicable.

Authors’ contributions
Conceptualization, XG, XQ and SW, Methodology, QW, Software, JW, Validation, QW and JW, Formal Analysis, YG, Investigation, YG and PS, Resources, YG and PS, Data Curation, YG, Writing – Original Draft Preparation, YG, Writing – Review & Editing, YG and QW, Visualization, SW, Supervision, XG, XQ and SW, Project Administration, XG, Funding Acquisition, XQ. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (81903085 and 82073114), the Project funded by China Postdoctoral Science Foundation (2020T102291 and 2019M651808), the Fundamental Research Funds for the Central Universities (201414380439), and Outstanding Young Talents Project by Nanjing Medical Science and technology development project (XQX21005). This work was also supported by the Project of Invigorating Health Care through Science, Technology and Education, Nanjing, China (no. ZDXKB2016015); and the Project of Outstanding Youth Training in Health Profession, Nanjing, China (no. QRX17012).

Availability of data and materials
Contact the author if need the datasets generated during and/or analysed during the current study.

Declarations
Ethics approval and consent to participate
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of Nanjing Drum Tower Hospital (protocol code: 2020-298-01, approval date: 10/26/2020). Patient consent was waived due to the specimen used in this retrospective study were at least 4 years ago.

Consent for publications
Not applicable.

Competing interests
None.

Author details
1 Medical School of Nanjing University, Nanjing 210093, Jiangsu, China. 2 Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing 210008, China. 3 Department of Otolaryngology Head and Neck Surgery, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Jiangsu Key Medical Discipline (Laboratory), Nanjing 210008, China. 4 Research Institute of Otolaryngology, Nanjing 210008, China. 5 Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing 210093, China. 6 Department of Otolaryngology Head and Neck Surgery, Affiliated Drum Tower Hospital, Medical School of Nanjing University, No.321 Zhongshan Road, Nanjing 210008, Jiangsu, China.

Received: 24 August 2021 Accepted: 13 January 2022
Published online: 14 March 2022

References
1. Gupta B, Johnson NW, Kumar N. Global epidemiology of head and neck cancers: a continuing challenge. Oncology. 2016;91(1):13–23.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Ca-a Cancer J Clin. 2019;69(1):7–34.
3. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
4. Dhull AK, et al. Major risk factors in head and neck cancer: a retrospective analysis of 12-year experiences. World J Oncol. 2018;9(3):80–4.
5. Liu Z, et al. Apoptotic capacity and risk of squamous cell carcinoma of the head and neck. Eur J Cancer. 2017;72:166–76.
6. Ang KK, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):34–5.
7. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010;15(9):994–1001.
8. Jou A, Hess J. Epidemiology and Molecular Biology of Head and Neck Cancer. Oncol Res Treat. 2017;40(6):328–32.
9. Qin H, et al. RNA-binding proteins in tumor progression. J Hematol Oncol. 2020;13(1):90.
10. Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10):3971–5.
11. Wei CM, Gershowitz A, Moss B. Methylated nucleotides block 5’ terminus of HeLa cell messenger RNA. Cell. 1975;4(4):379–86.
12. Zhao BS, Roundtree IA, He C. Post-transcriptional gene regulation by mRNAs modifications. Nat Rev Mol Cell Biol. 2017;18(1):31–42.
13. Alarcón CR, Lee H, Goodarzi H, Halberg N, Tavazoie SF. N6-methyladenosine marks primary microRNAs for processing. Nature. 2015;519(7544):4.
14. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20(10):608–24.
15. Huang W, et al. N6-methyladenosine methyltransferases: functions, regulation, and clinical potential. J Hematol Oncol. 2021;14(1):1–19.
16. Deng X, et al. Role of N6(methyladenosine methyltransferases in the late 20th and early 21st century: a period analysis. Oncologist. 2018;24(1):1–7.
17. Wei W, et al. Regulatory role of N6(methyladenosine (m6A) methylation in RNA processing and human diseases. J Cell Biochem. 2017;118(9):2534–43.
18. Zhao Y, et al. m6A-binding proteins: the emerging crucial performers in epigenetics. J Hematol Oncol. 2020;13(1):35.
19. Dominissini D, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201–6.
20. Huang W, et al. Determination of DNA and RNA methylation in circulating tumor cells by mass spectrometry. Anal Chem. 2016;88(2):1378–84.
21. Barbieri I, et al. Promoter-bound METTL3 maintains myeloid leukemia by m6A-dependent translation control. Nature. 2017;552(7683):126–31.
22. O’Connor L, Gilmour J, Bonifer C. The role of the ubiquitously expressed transcription factor Sp1 in tissue-specific transcriptional regulation and in disease. Yale J Biol Med. 2016;89(4):153–25.

23. Wang Q, et al. Mettl3-mediated m6A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. Gut. 2020;69(7):1193–205.

24. Wang Q, et al. Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer. J Hematol Oncol. 2020;13(1):1–10.

25. Taketo K, et al. The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells. Int J Oncol. 2018;52(6):2621–9.

26. Cai X, et al. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7c. Cancer Lett. 2018;415:1–11.

27. Chen MN, et al. RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent post-transcriptional silencing of SOCS2. Hepatology. 2018;67(6):2254–70.

28. Du MJ, et al. MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA. Biochem Biophys Res Commun. 2017;482(4):582–9.

29. Zhang PP, et al. m6A-mediated ZNF750 repression facilitates nasopharyngeal carcinoma progression. Cell Death Dis. 2018;9:1–12.

30. Hua WF, et al. METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition. Gynecol Oncol. 2018;151(2):356–65.

31. Jin D, et al. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-mir-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis (vol 135, 2019). J Hematol Oncol. 2020;13(1):1–22.

32. Ledermann J, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61.

33. De Souza CPC, Ellem KA0, Gabrielli BG. Centrosomal and cytoplasmic cdc2/cyclin B1 activation precedes nuclear mitotic events. Exp Cell Res. 2000;257(1):11–21.

34. Lindqvist A, et al. Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome. J Cell Biol. 2005;171(17):35–45.

35. Bugaré B, et al. Genotoxic-activated G(2)-M checkpoint exit is dependent on CDC25B phosphate expression. Mol Cancer Ther. 2006;5(6):1446–51.

36. Boutros R, Lobioñ v, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer. 2007;7(7):495–507.

37. Cao SG, et al. Halsaquinone and xestosponnine derivatives, inhibitors of Cdc25c phosphate from a Xestospongia sp. Bioorg Med Chem. 2005;13(4):999–1003.

38. Lazo JS, et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity phosphatase Cdc25. J Med Chem. 2001;44(24):4942–9.

39. Bona AE, Calcagno DQ, Ribeiro HF, Muniz JA, et al. Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer. Ther Adv Gastroenterol. 2020;13:1–13.

40. Lili L, Ruili Z, Meng L, Yuru X. Promoter region CpG island methylation and tumor suppression in triple negative breast cancer. NAR Cancer. 2003;63(19):6195–9.

41. Puttipatyaleers C, et al. Alu hypomethylation in smoke-exposed epithelia and oral squamous carcinoma. Asian Pac J Cancer Prev. 2013;14(9):5495–501.

42. Chen HC, et al. Global DNA hypomethylation is associated with the development and poor prognosis of tongue squamous cell carcinoma. J Oral Pathol Med. 2016;45(6):409–17.

43. Alyaïri NS, et al. Aberrant promoter methylation of PTEN gene among Indian patients with oral squamous cell carcinoma. Int J Biol Markers. 2013;28(3):298–302.

44. Sushma PS, et al. PTEN and p16 genes as epigenetic biomarkers in oral squamous cell carcinoma (OSCC): a study on south indian population. Tumor Biol. 2016;37(6):7625–32.

45. Li JB, et al. Aberrant CpG island methylation of PTEN is an early event in nasopharyngeal carcinoma and a potential diagnostic biomarker. Oncol Rep. 2014;31(5):2206–12.

46. Bocciaietto P, et al. MODOMiRC: a database of RNA modification pathways 2017 update. Nucleic Acids Res. 2018;46(D1):D303–7.